natgillin/translations-raw huggingface dataset:
Total volume of Removab concentrate for solution for infusion
Skupni volumen zdravila Removab koncentrata za raztopino za infundiranje
• The entire content of the syringe (Removab concentrate plus air buffer) is injected from the pre-filled syringe directly into the sodium chloride 9 mg/ml (0.9%) solution for injection.
• Injicirajte celotno vsebino brizge (koncentrat zdravila Removab z zračnim pufrom) iz napolnjene brizge neposredno v raztopino natrijevega klorida 9 mg/ml za injiciranje (0,9 %).
1 pre-filled syringe.
1 napolnjena injekcijska brizga
Removab is given as 4 intraperitoneal infusions with increasing dose (10, 20, 50 and 150 micrograms), separated at least by 2 infusion-free calendar days (for example you will receive infusion on day 0, 3, 7, 10).
150 mikrogramov), med katerimi morata biti vsaj 2 koledarska dneva brez infundiranja (infuzijo boste na primer prejeli na dan 0, 3, 7, 10).
Talk to your doctor or nurse before using Removab.
Pred začetkom uporabe zdravila Removab se posvetujte s svojim zdravnikom ali medicinsko sestro.
Subsequently, prior to each Removab administration 500 ml sodium chloride 9 mg/ml (0.9%) solution for injection shall be infused to support distribution of the antibody in the abdominal cavity.
Nato se v trebušno votlino infundira 500 ml raztopine natrijevega klorida 9 mg/ml (0,9 %) za injiciranje za podporo porazdelitve protiteles.
Respiratory, thoracic and mediastinal disorders Common
Bolezni dihal, prsnega koša in mediastinalnega prostora
Puncture free survival
Preživetje brez punktiranja Mediano preživetje brez punktiranja
Transient increase in hepatic enzymes was commonly observed after the administration of Removab.
Po uporabi zdravila Removab so pogosto opažali prehodno zvišanje jetrnih encimov.
50 ml Syringe
50 ml brizga
In one patient (0.1%) dyspnoea and in 3 patients (0.4%) hypotension was reported in CTCAE grade 4 intensity.
3 bolnikih (0,4 %) so poročali o hipotenziji 4. stopnje po CTCAE.
• The pre-filled syringe cannula is inserted through the 50 ml syringe opening so that the cannula is immersed in the sodium chloride 9 mg/ml (0.9%) solution for injection (Figure 2).
• Vstavite kanilo napolnjene injekcijske brizge skozi odprtino 50 ml brizge tako, da se kanila potopi v raztopino natrijevega klorida 9 mg/ml (0,9 %) za injiciranje (Slika 2).
gastric disorder, ileus*, gastroesophageal reflux disease, dry mouth.
Zaprtje*, dispepsija, trebušna distenzija, subileus*, flatulenca, želodčne motnje, ileus*, gastroezofagealna refluksna bolezen, suha usta
The catheter for intraperitoneal administration should be placed under ultrasound guidance by a physician experienced in intraperitoneal administration procedures.
Zdravnik z izkušnjami pri postopkih intraperitonealne uporabe zdravila nastavi kateter za intraperitonealno apliciranje pod ultrazvočnim vodenjem.
The catheter is used for ascites drainage and infusion of diluted Removab and sodium chloride 9 mg/ml (0.9%) solution for injection.
Kateter se uporablja za drenažo ascitesa in infundiranje zdravila Removab in raztopine natrijevega klorida 9 mg/ml (0,9 %).
Patients with renal impairment of a higher severity grade than mild have not been investigated.
Okvarjeno delovanje ledvic Pri bolnikih z okvaro delovanja ledvic, ki presega blago, raziskav niso opravili.
Do not use Removab - if you are allergic to catumaxomab or any of the other ingredients of this medicine (listed in section 6) - if you are allergic to murine proteins (from rat and / or mouse)
Kaj morate vedeti, preden boste uporabili zdravilo Removab Ne uporabljajte zdravila Removab - če ste alergični na katumaksomab ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Intraperitoneal use only, after dilution.
Samo za intraperitonealno uporabo po razredčitvi.
Pain, asthenia*, Systemic inflammatory response syndrome*, oedema incl.
Bolečine, astenija*, sindrom sistemskega vnetnega odziva*, edem,
3rd infusion 50 micrograms
3. infuzija 50 mikrogramov
Removab must not be administered as a bolus or by any route other than intraperitoneally.
4.4 Posebna opozorila in previdnostni ukrepi Zdravila Removab se ne sme uporabljati kot bolusni odmerek ali na kakršen koli drugačen način kot intraperitonealno.
Any air bubble(s) from the 50 ml syringe is eliminated.
Iz 50 ml brizge odstranite vse zračne mehurčke.
Removab must not be administered by intraperitoneal bolus or by any other route of administration.
Zdravila Removab se ne sme dati v obliki intraperitonealnega bolusnega odmerka ali na kak drugačen način.
Median overall survival (days) 95% CI for median (days) p-value (log-rank test) Hazard ratio (HR) (Catumaxomab versus Catumaxomab + Prednisolone) 95% CI for HR
95 % IZ za mediano (dni) Vrednost p (test log-rank) Razmerje tveganja (RT) (katumaksomab v primerjavi s katumaksomabom + prednizolonom) 95 % IZ za RT
95% CI for HR
Razmerje tveganja (RT) 95 % IZ za RT
Table 6 Overall survival of study IP-CAT-AC-03 in post study phase Catumaxomab (N=108)
Preglednica 6 Celokupno preživetje študije IP-CAT-AC-03 v fazi po študiji
How to store Removab
Shranjevanje zdravila Removab
Common serious side effects (may affect up to 1 in 10 people): - Loss of appetite - Dehydration - Reduction in red blood cells (anaemia) - Decreased blood levels of calcium and sodium - A very fast heart beat - High or low blood pressure - Abdominal pain accompanied by difficulty or blockage passing stools, constipation - Shortness of breath - Accumulation of fluid around the lungs which cause chest pain and breathlessness - Inflammation of the bile ducts - Skin redness, rash - Very fast heartbeat, fever, shortness of breath, feeling faint or light-headed - Complex of reactions due to the release of mediators of inflammation - Worsening of general state of health, generally feeling unwell and weak - Fluid retention - Hypersensitivity
- zastajanje tekočine okoli pljuč, kar povzroča bolečine v prsih in zasoplost, - vnetje žolčevodov, - pordelost kože, izpuščaj, - zelo hiter srčni utrip, zvišana telesna temperatura, zasoplost, občutek omedlevanja ali prazne glave, - kompleksna reakcija zaradi sproščanja mediatorjev vnetja,
Pharmacokinetics of catumaxomab during and after four intraperitoneal infusions of 10, 20, 50 and 150 micrograms catumaxomab were investigated in 13 patients with symptomatic malignant ascites due to EpCAM-positive carcinomas.
Pri 13 bolnikih s simptomatičnim malignim ascitesom zaradi karcinoma, pozitivnega na EpCAM, so raziskali farmakokinetiko katumaksomaba med štirimi intraperitonealnimi infuzijami s po 10, 20, 50 in 150 mikrogrami katumaksomaba in po njih.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton: Removab 10 micrograms
PODATKI NA ZUNANJI OVOJNINI Škatla: Removab 10 mikrogramov
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton: Removab 50 micrograms
PODATKI NA ZUNANJI OVOJNINI Škatla: Removab 50 mikrogramov
Plasma levels tended to decline after achieving a maximum after each dose.
Po doseženi največji vrednosti po vsakem odmerjanja so začele koncentracije v plazmi padati.
Paracentesis (control) (N=88)
skupina) (N = 88)
• The enclosed cannula is attached to the Removab pre-filled syringe.
• Priloženo kanilo nataknite na injekcijsko brizgo, napolnjeno z zdravilom Removab.
Very common Abdominal pain*, nausea*, vomiting*, diarrhoea*.
Bolečine v trebuhu*, navzea*, bruhanje*, driska*
One pre-filled syringe contains 50 micrograms catumaxomab in 0.5 ml solution, corresponding to 0.1 mg/ml.
Ena napolnjena injekcijska brizga vsebuje 50 mikrogramov katumaksomaba v 0,5 ml raztopine, kar ustreza 0,1 mg/ml.
Dyspnoea and hypo-/ hypertension are commonly observed.
Pogosto so opazili dispnejo, hipotenzijo ali hipertenzijo.
A perfusion tubing of an inner diameter of 1 mm and a length of 150 cm must be used.
Uporabite perfuzijsko cevko notranjega premera 1 mm in dolžine 150 cm. • Povežite perfuzijsko cevko s spojem Y.
One pre-filled syringe contains 10 micrograms catumaxomab in 0.1 ml solution, corresponding to 0.1 mg/ml.
Ena napolnjena injekcijska brizga vsebuje 10 mikrogramov katumaksomaba v 0,1 ml raztopine, kar ustreza 0,1 mg/ml.
Treatment:
zdravljenja.
Removab 50 micrograms concentrate for solution for infusion catumaxomab
Removab 50 mikrogramov koncentrat za raztopino za infundiranje katumaksomab
Removab 10 micrograms concentrate for solution for infusion catumaxomab
Removab 10 mikrogramov koncentrat za raztopino za infundiranje katumaksomab
Ear and labyrinth disorders Common
Ušesne bolezni, vključno z motnjami labirinta
Cytokine release syndrome*, hypersensitivity*.
Sindrom sproščanja citokina*, preobčutljivost* Presnovne in prehranske motnje
Tachycardia*, incl.
Tahikardija*, vklj.
Sodium citrate Citric acid monohydrate Polysorbate 80
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi natrijev citrat citronska kislina monohidrat polisorbat 80 voda za injekcije
Abdominal pain
Pediatrična populacija
What Removab contains - The active substance is catumaxomab (50 micrograms in 0.5 ml, corresponding to 0.1 mg/ml).
- Zdravilna učinkovina je katumaksomab (50 mikrogramov v 0,5 ml, kar ustreza 0,1 mg/ml).
• Sodium chloride 9 mg/ml (0.9%) solution for injection
Potrebno je tudi naslednje: • natrijev klorid 9 mg/ml (0,9 %) raztopina za injiciranje
What Removab contains - The active substance is catumaxomab (10 micrograms in 0.1 ml, corresponding to 0.1 mg/ml).
- Zdravilna učinkovina je katumaksomab (10 mikrogramov v 0,1 ml, kar ustreza 0,1 mg/ml).
QUALITATIVE AND QUANTITATIVE COMPOSITION One pre-filled syringe contains 10 micrograms of catumaxomab* in 0.1 ml solution, corresponding to 0.1 mg/ml.
Ena napolnjena injekcijska brizga vsebuje 10 mikrogramov katumaksomaba* v 0,1 ml raztopine, kar ustreza 0,1 mg/ml.
Sodium chloride 9 mg/ml (0.9%) solution for injection
Natrijev klorid 9 mg/ml raztopina za injiciranje
NAME OF THE MEDICINAL PRODUCT Removab 50 micrograms concentrate for solution for infusion catumaxomab
Navodilo za uporabo Removab 50 mikrogramov koncentrat za raztopino za infundiranje katumaksomab
NAME OF THE MEDICINAL PRODUCT Removab 10 micrograms concentrate for solution for infusion catumaxomab
Navodilo za uporabo Removab 10 mikrogramov koncentrat za raztopino za infundiranje katumaksomab
QUALITATIVE AND QUANTITATIVE COMPOSITION One pre-filled syringe contains 50 micrograms of catumaxomab* in 0.5 ml solution, corresponding to 0.1 mg/ml.
Ena napolnjena injekcijska brizga vsebuje 50 mikrogramov katumaksomaba* v 0,5 ml raztopine, kar ustreza 0,1 mg/ml.
Metabolism and nutrition disorders Common
Infekcijske in parazitske bolezni
• The tip cap from the Removab pre-filled syringe is removed with the tip pointing up.
• Odstranite pokrov konice z injekcijske brizge, napolnjene z zdravilom Removab, tako da gleda konica brizge navzgor.
Infusion-related side effects
Z infundiranjem povezani neželeni učinki
Gastrointestinal disorders
Paracenteza + katumaksomab
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Pre-filled syringe: Removab 10 micrograms
Napolnjena injekcijska brizga: Removab 10 mikrogramov
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Blister: Removab 50 micrograms
Pretisni omot: Removab 50 mikrogramov
Performance status and BMI
Status telesne zmogljivosti in indeks telesne mase
Cardiac disorders Common
Srčne bolezni
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Pre-filled syringe: Removab 50 micrograms
Napolnjena injekcijska brizga: Removab 50 mikrogramov
Number of Removab pre-filled syringe(s)
Sindrom sistemskega vnetnega odziva (SIRS)
Removab contains the active substance catumaxomab, a monoclonal antibody.
Kaj je zdravilo Removab in za kaj ga uporabljamo Zdravilo Removab vsebuje zdravilno učinkovino imenovano katumaksomab, ki je monoklonsko protitelo.
If you feel dizzy, do not drive or use any tools or machines.
Če ste omotični, ne vozite avta in ne uporabljajte orodja ali strojev.
• Blood or sugar in your urine.
• kri ali sladkor v urinu,
National or local guidance should be taken into consideration.
Upoštevati je treba nacionalne ali lokalne smernice.
The possibility of sensitisation should be taken into account.
Upoštevati je treba tudi možnost senzibilizacije.
The signs may include:
Ti znaki lahko vključujejo:
If you miss an injection, you should have it as soon as possible.
Če izpustite injekcijo, jo morate prejeti takoj, ko je mogoče.
Symptomatic treatment is recommended in these cases.
V teh primerih se priporoča simptomatsko zdravljenje.
The duration of therapy varies according to the course of the disease.
Trajanje zdravljenja se razlikuje glede na potek bolezni.
Caution should be particularly considered in the paediatric population.
Previdnost je potrebna zlasti pri pediatrični populaciji.
Patients should be cautious when driving or operating machinery.
Bolniki morajo biti med vožnjo ali upravljanjem s stroji previdni.
However, if it is almost time for your next injection, skip the missed injection.
Če pa je že skoraj čas za naslednjo injekcijo, preskočite injekcijo, ki ste jo pozabili.
Consideration should be given to official guidelines on the appropriate use of antibacterial agents.
Upoštevati je treba uradne smernice o ustrezni uporabi protimikrobnih učinkovin.
(Groups A, B, C and G)
(skupine streptokokov A, B, C in G)
The incidence appears to be lower with slow infusion (20 - 30 minutes).
Kaže, da je incidenca pri počasnem infundiranju nižja (20-30 minut).
Do not take a double dose (two injections at the same time) to make up for a missed dose.
Ne uporabite dvojnega odmerka (dveh injekcij sočasno), če ste pozabili uporabiti prejšnji odmerek.
Treatment frequency**
Pogostnost zdravljenja**
In older people aged over 75 years the average elimination half-life is usually two to three times that of young adults.
Pri osebah, starejših od 75 let, je povprečni razpolovni čas izločanja običajno dva- do trikrat daljši kot pri mladih odraslih osebah.
It works by killing bacteria that cause infections.
Deluje tako, da ubije bakterije, ki povzročajo okužbe.
Species for which acquired resistance may be a problem
Vrste, pri katerih je lahko problem pridobljena odpornost
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
Preden boste dobili to zdravilo, natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
Bacterial resistance to ceftriaxone may be due to one or more of the following mechanisms:
Do bakterijske odpornosti na ceftriakson lahko pride zaradi enega ali več naslednjih mehanizmov:
The number of days or weeks that you are given Rocephin depends on what sort of infection you have.
Število dni ali tednov, ko boste zdravilo Rocephin prejemali, je odvisno od vrste okužbe, ki jo imate.
Since these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorised as not known.
Ker te učinke poročajo prostovoljno iz populacije neznane velikosti, ni mogoče zanesljivo oceniti njihove pogostnosti, zato je kategorizirana kot neznana.
If you need a blood or urine test
Če morate opraviti krvne ali urinske preiskave
In children, prospective studies have shown a variable incidence of precipitation with intravenous application - above 30 % in some studies.
Pri otrocih so prospektivne študije pokazale spremenljivo incidenco obarjanja pri intravenskemu dajanju - v nekaterih študijah nad 30 %.
• A secondary infection that may not respond to the antibiotic previously prescribed
• sekundarna okužba, ki se ne odziva na predhodno predpisani antibiotik,
+ Resistance rates >50% in at least one region % ESBL producing strains are always resistant
+ stopnja odpornosti > 50 % v najmanj eni regiji % sevi, ki proizvajajo β-laktamaze z razširjenim spektrom delovanja (ESBL), so vedno odporni
• to prevent infections during surgery.
• za preprečevanje okužb med kirurškim posegom.
During childhood, the half-life is lower than in neonates or adults.
Med otroštvom je razpolovni čas nižji kot pri novorojencih ali odraslih.
• You have recently had diarrhoea after having an antibiotic medicine.
• če ste pred kratkim imeli drisko po uporabi antibiotika.
If you are given Rocephin for a long time, you may need to have regular blood tests.
Če zdravilo Rocephin prejemate dolgo časa, je morda treba pri vas opravljati redne krvne preiskave.
In particularly severe cases, doses at the higher end of the recommended range should be considered.
V posebno hudih primerih je treba razmisliti o odmerkih v zgornjem delu priporočenega razpona.
Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:
Mejne vrednosti minimalne inhibitorne koncentracije (MIC, minimum inhibitory concentration), kot jih je ugotovil Evropski odbor za testiranje protimikrobne občutljivosti (EUCAST, European Committee on Antimicrobial Susceptibility Testing), so naslednje:
A maximum daily dose of 50 mg/kg should not be exceeded.
Maksimalnega dnevnega odmerka 50 mg/kg ne smemo prekoračiti.
In particular, tell your doctor or pharmacist if you are taking any of the following medicines:
Zdravnika ali farmacevta še zlasti obvestite, če jemljete katero od naslednjih zdravil:
The doses recommended in the tables below are the generally recommended doses in these indications.
Odmerki, priporočeni v spodnjih preglednicah, so na splošno priporočeni odmerki za te indikacije.
The risk of precipitate formation is increased in immobilized or dehydrated patients.
Tveganje za nastanek oborin je pri imobiliziranih ali dehidriranih bolnikih povečano.
Dilution Test (MIC, mg/L)
Test redčenja (MIC, mg/l) Občutljivi
The elimination half-life of total ceftriaxone in adults is about 8 hours.
Razpolovni čas izločanja skupnega ceftriaksona pri odraslih je približno 8 ur.
Renal clearance is 5 - 12 ml/min.
Ledvični očistek je 5-12 ml/min.
Concentrations for the intravenous injection: 100 mg/ml, Concentrations for the intravenous infusion: 50 mg/ml (Please refer to section 4.2 for further information).
Koncentracije za intravensko injekcijo: 100 mg/ml Koncentracije za intravensko infuzijo: 50 mg/ml (Prosimo glejte poglavje 4.2 za dodatne informacije).
Your doctor will decide the correct dose of Rocephin for you.
Zdravnik bo določil ustrezni odmerek zdravila Rocephin za vas.
The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections.
Prevalenca pridobljene odpornosti se lahko pri določenih vrstah razlikuje glede na zemljepisno lego in čas, zato je zaželeno, da dobite lokalne informacije o odpornosti še zlasti pri zdravljenju hudih okužb.
If your daily dose is higher than 2 g, you may receive it as a single dose once a day or as two separate doses.
Če je vaš dnevni odmerek višji od 2 g, ga lahko prejmete v enkratnem odmerku enkrat na dan ali kot dva ločena odmerka.
Only in cases of preterminal renal failure (creatinine clearance < 10 ml/min) should the ceftriaxone dosage not exceed 2 g daily.
Le v primerih preterminalne ledvične odpovedi (očistek kreatinina < 10 ml/min) odmerek ceftriaksona ne sme preseči 2 g na dan.
Intravenous intermittent injection should be given over 5 minutes preferably in larger veins.
Intervensko intermitentno injekcijo je treba dati v času 5 minut po možnosti v večjo veno.
Rocephin is usually given by a doctor or nurse.
Zdravilo Rocephin vam bo običajno dal zdravnik ali medicinska sestra.
Rocephin can affect the results of urine tests for sugar and a blood test known as the Coombs test.
Zdravilo Rocephin lahko vpliva na rezultate urinskih preiskav za sladkor in na krvno preiskavo, znano pod imenom Coombsov test.
Your doctor will decide how much Rocephin you will need and will check you closely depending on the severity of the liver and kidney disease.
Vaš zdravnik se bo odločil, koliko zdravila Rocephin potrebujete, in vas skrbno spremljal glede na resnost bolezni jeter in ledvic.
• A high temperature (fever).
• visoka telesna temperatura (vročina)
• 1 to 2 g once a day depending on the severity and type of infection.
• od 1 do 2 g enkrat na dan, odvisno od resnosti in vrste okužbe.
the blood.
• krvi,
During prolonged treatment complete blood count should be performed at regular intervals.
Med dolgotrajnim zdravljenjem je treba v rednih intervalih opravljati krvne preiskave s celotno krvno sliko.
50 - 60 % of ceftriaxone is excreted unchanged in the urine, primarily by glomerular filtration, while 40 - 50 % is excreted unchanged in the bile.
50-60 % ceftriaksona se nespremenjenega izloči z urinom, zlasti s pomočjo glomerularne filtracije, medtem ko se 40-50 % nespremenjenega izloči z žolčem.
This should be taken into consideration in patients on a controlled sodium diet.
To morajo upoštevati bolniki, ki so na dieti z nadzorovanim vnosom natrija.
As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of ceftriaxone in at least some types of infections is questionable.
Po potrebi je treba poiskati nasvet strokovnjaka, če je lokalna prevalenca odpornosti takšna, da je uporabnost ceftriaksona vprašljiva pri vsaj nekaterih vrstah okužb.
Close clinical monitoring for safety and efficacy is advised.
Priporoča se natančno klinično spremljanje varnosti in učinkovitosti.
Ceftriaxone should only be administered during pregnancy and in particular in the first trimester of pregnancy if the benefit outweighs the risk.
Ceftriakson se lahko med nosečnostjo, zlasti v prvem trimesečju, daje le, če so koristi večje od tveganj.
From birth to 14 days of age, the levels of free ceftriaxone may be further increased by factors such as reduced glomerular filtration and altered protein binding.
Od rojstva do starosti 14 dni se lahko ravni prostega ceftriaksona še povečajo zaradi dejavnikov, kot sta zmanjšana glomerularna filtracija in spremenjena vezava na beljakovine.
Newborn babies (0-14 days)
Novorojenci (0-14 dni)
• You are allergic to ceftriaxone or any of the other ingredients of this medicine (listed in section 6).
• če ste alergični na ceftriakson ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Inherently resistant organisms
Inherentno odporni organizmi
At least one of them had received ceftriaxone and calcium at different times and through different intravenous lines.
Vsaj en od njih je prejel ceftriakson in kalcij ob različnem času in skozi različne intravenske linije.
• You have recently received or are about to receive products that contain calcium.
• če ste pred kratkim prejeli ali pa boste prejeli zdravila, ki vsebujejo kalcij.
There are no study data in patients with severe hepatic impairment (see section 5.2).
Podatkov iz študij za bolnike s hudo jetrno okvaro ni (glejte poglavje 5.2).
• The baby is premature.
• če je dojenček nedonošen.
• You have had a sudden or severe allergic reaction to penicillin or similar antibiotics (such as cephalosporins, carbapenems or monobactams).
• če ste imeli nenadno ali hudo alergijsko reakcijo na penicilin ali podobne antibiotike (kot so cefalosporini, karbapenemi ali monobaktami).
• An antibiotic called chloramphenicol (used to treat infections, particularly of the eyes).
• Antibiotik, imenovan kloramfenikol (uporablja se za zdravljenje okužb, zlasti oči).
• A false positive result in a Coombs' test (a test for some blood problems).
• lažno pozitivni rezultati Coombsovega testa (preiskava za nekatere težave s krvjo),
The plasma clearance and volume of distribution of total ceftriaxone are greater in neonates, infants and children than in adults.
Očistek v plazmi in volumen distribucije skupnega ceftriaksona sta pri novorojencih, dojenčkih in otrocih večja kot pri odraslih.
Do not stop taking Rocephin unless your doctor tells you to.
Če ste prenehali uporabljati zdravilo Rocephin Ne prenehajte jemati zdravila Rocephin, razen če vam to naroči vaš zdravnik.
Superinfections with non-susceptible micro-organisms may occur as with other antibacterial agents.
Pojavijo se lahko superinfekcije z neobčutljivimi mikroorganizmi, tako kot pri drugih protimikrobnih učinkovinah.
Concomitant use with oral anticoagulants may increase the anti-vitamin K effect and the risk of bleeding.
Sočasna uporaba s peroralnimi antikoagulanti lahko poveča učinek nasproten vitaminu K in tveganje za krvavitev.